GlassScriptPhysician profile
Brad M Dajani
NPI 1659494854
$72,570.26
in general payments reported to CMS, 2019-2025
76 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,889 · 2021: $10K · 2022: $15K · 2023: $9,003 · 2024: $10K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26K · Consulting Fee: $5,010 · Travel and Lodging: $864 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26,485.60 |
| Consulting Fee | $5,010.00 |
| Travel and Lodging | $863.63 |
| Education | $316.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $12,661.07 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $5,752.98 | 2019-2025 | Zilbrysq, Fintepla, Rystiggo |
| Abbvie INC. | $3,790.96 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Acadia Pharmaceuticals INC | $3,243.07 | 2019-2025 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $3,203.34 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $3,047.98 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $2,839.09 | 2019-2025 | |
| Biogen, INC. | $2,544.24 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Biohaven Pharmaceuticals, INC. | $2,453.20 | 2020-2021 | |
| Emd Serono, INC. | $2,364.61 | 2019-2025 | Mavenclad, Mavenclad |
| Amneal Pharmaceuticals LLC | $1,812.26 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Avanir Pharmaceuticals, INC. | $1,748.56 | 2019-2022 | |
| Eisai INC. | $1,707.89 | 2019-2025 | |
| Genzyme Corporation | $1,687.29 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $1,634.16 | 2022-2025 | Ingrezza, Ongentys |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,411.58 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amgen INC. | $1,267.31 | 2019-2023 | Aimovig |
| Livanova USA, INC. | $1,264.98 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Otsuka America Pharmaceutical, INC. | $1,217.56 | 2023-2025 | Rexulti, Nuedexta |
| Neurelis, INC. | $1,071.09 | 2020-2024 | Valtoco |
| Allergan, INC. | $1,021.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,010.31 | 2021-2023 | Ponvory |
| Zyla Life Sciences, INC. | $982.20 | 2019-2020 | |
| Pfizer INC. | $932.29 | 2019-2025 | |
| Mdd US Operations, LLC | $888.74 | 2019-2024 | Gocovri, Apokyn, Apokyn |
| Acorda Therapeutics, INC | $700.33 | 2019-2024 | Inbrija, Ampyra |
| E.R. Squibb & Sons, L.L.C. | $690.67 | 2020-2025 | Zeposia |
| Sk Life Science, INC. | $669.87 | 2020-2025 | |
| Tanabe Pharma America, INC. | $569.03 | 2019-2025 | Radicava |
| Merz Pharmaceuticals, LLC | $563.74 | 2021-2025 | Xeomin, Inbrija |
| Janssen Biotech, INC. | $511.94 | 2025 | |
| Mallinckrodt Hospital Products INC. | $496.25 | 2020-2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $480.51 | 2022 | |
| Sunovion Pharmaceuticals INC. | $468.32 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $436.54 | 2022-2024 | Amvuttra, Onpattro |
| Impel Pharmaceuticals INC. | $417.34 | 2022-2023 | Trudhesa |
| Ani Pharmaceuticals, INC. | $406.21 | 2023-2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $400.92 | 2020-2025 | Vyepti, Rexulti |
| Celgene Corporation | $381.98 | 2020-2025 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $282.03 | 2025 | Wainua |
| Supernus Pharmaceuticals, INC. | $272.16 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $266.27 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $221.57 | 2023-2024 | Aptiom |
| C2n Diagnostics, LLC | $218.71 | 2025 | Precivityad2 |
| Medtronic, INC. | $206.17 | 2024-2025 | Intellis Adaptivestim, Synchromedii |
| Genentech USA, INC. | $204.30 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Merck Sharp & Dohme LLC | $200.72 | 2020-2023 | Belsomra |
| Mallinckrodt Enterprises LLC | $188.28 | 2019 | |
| Kyowa Kirin, INC. | $184.55 | 2020-2021 | |
| Harmony Biosciences LLC | $158.55 | 2020-2021 | |
| Grifols USA, LLC | $156.22 | 2019 | |
| Merz North America, INC. | $145.92 | 2019-2020 | |
| Stryker Corporation | $137.04 | 2019 | |
| Nevro Corp. | $125.57 | 2023 | Senza |
| Upsher-Smith Laboratories LLC | $104.79 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $71.35 | 2021 | |
| Aucta Pharmaceuticals, INC. | $70.30 | 2025 | Motpoly Xr |
| Abbott Laboratories | $70.29 | 2024-2025 | Infinity, Eterna |
| Avion Pharmaceuticals | $64.14 | 2022-2023 | Dhivy |
| Axsome Therapeutics, INC. | $49.19 | 2025 | Symbravo |
| Akcea Therapeutics, INC. | $47.98 | 2019-2020 | |
| Corium, LLC | $45.99 | 2022-2023 | Adlarity |
| Greenwich Biosciences, INC. | $40.36 | 2019-2021 | |
| Kvk-Tech, INC. | $35.65 | 2019 | |
| Promius Pharma LLC | $34.97 | 2019 | |
| Eli Lilly and Company | $27.67 | 2025 | Kisunla, Amyvid |
| Vanda Pharmaceuticals INC. | $25.91 | 2025 | Ponvory |
| Assertio Therapeutics, INC. | $25.84 | 2020 | |
| Scilex Pharmaceuticals INC. | $23.07 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.69 | 2025 | Keveyis |
| Insightec,INC | $20.08 | 2024 | Exablate |
| Csl Behring | $15.50 | 2020 | |
| Cala Health, INC. | $14.97 | 2023 | Cala Trio |
| Octapharma USA, INC. | $14.87 | 2025 | Panzyga |
| Penumbra, INC. | $14.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Dajani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.